Reduce Downstream Processing Costs for mAbs by Switching to Tosoh’s 2-Step Platform
contributed by Tosoh |
Downstream processing is responsible for up to 80 percent of the entire production costs of biotherapeutics. Given the current drive to reduce the cost of manufacturing for biological therapeutics, streamlining downstream processing is a necessity for chromatographers and process engineers.
In this study, we showcase the benefits of Tosoh’s 2-step process for the purification of monoclonal antibodies (mAb) in comparison to the standard industrial process. Combining high-performance Protein A capturing and a single polishing step on salt-tolerant anion exchange resin, we could reduce the downstream costs by 45 % and increase the production output by 58 %.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine